Quick Overview

High-purity Tesamorelin, a synthetic growth hormone-releasing hormone (GHRH) analog characterized by an N-terminal hexenoyl modification, synthesized specifically for in vitro laboratory research and development. Formulated as a sterile, lyophilized powder to ensure maximum stability and precision in endocrine, pituitary signaling, and receptor binding assay models.

Product Description

Tesamorelin is a synthetic 44-amino-acid peptide analog of human growth hormone-releasing hormone (GHRH) featuring an attached 3-hexenoyl group at its N-terminal tyrosine residue. This structural modification enhances enzymatic resistance against rapid systemic degradation and increases peptide potency compared to native GHRH. In scientific literature, Tesamorelin is extensively investigated for its specific interactions with the GHRH receptor (GHRH-R), downstream pituitary stimulation kinetics, and cellular metabolic regulatory pathways. In vitro culture models use Tesamorelin to examine growth hormone secretagogue responses and lipid metabolism signaling parameters.

Common Research Applications:

• GHRH Receptor Kinetics: Investigating high-affinity binding and activation pathways of pituitary GHRH receptors.
• Enzyme Resistance & Stability: Assessing the pharmacokinetic enhancements conferred by the N-terminal hexenoyl modification against peptidase breakdown.
• Endocrine Pathway Analysis: Observing cellular synthesis and release mechanisms associated with growth hormone secretagogues.
• Metabolic Assay Optimization: Analyzing cellular signaling dynamics linked to lipid metabolism models.

Technical Specifications

Storage and Reconstitution

To maintain peptide integrity and stability, please adhere to standard laboratory handling guidelines:

• Lyophilized Form (Dry Powder): Store desiccated at -20°C (or below) upon receipt. While stable at room temperature for brief transit periods, long-term freezing is required to prevent degradation.
• Reconstitution: Reconstitute using bacteriostatic water or sterile water for injection. Introduce the diluent carefully and gently swirl the vial until dissolved. Do not shake vigorously, as this can fracture the peptide bonds.
• Liquid Storage (Reconstituted): Once reconstituted, the solution should be stored at 2°C to 8°C (refrigerated) and utilized within 14 to 30 days. For extended experimental timelines, aliquot the solution into individual vials and freeze at -20°C to avoid repeated freeze-thaw cycles.

Regulatory & Safety Disclaimer